{"id":2776,"date":"2024-01-17T09:04:58","date_gmt":"2024-01-17T09:04:58","guid":{"rendered":"https:\/\/medxelerator.com\/?p=2776"},"modified":"2024-01-17T09:04:58","modified_gmt":"2024-01-17T09:04:58","slug":"exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us","status":"publish","type":"post","link":"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/","title":{"rendered":"Exero Medical\u2019s Pivotal Clinical Study of xBar Approved by WCG in the US"},"content":{"rendered":"

Enrollment to commence in Q1 2024<\/strong><\/h3>\n

Or Yehuda, Israel, January 17, 2024 — Exero Medical\u2019s prospective, blinded, multi-center study of xBar has been approved by the WCG.<\/p>\n

The study, expected to commence during Q1 2024 at several leading US and Israeli hospitals, will enroll about 190 patients undergoing colorectal resection.\u00a0 It will evaluate the performance of Exero Medical\u2019s flagship device, xBar, in accurately monitoring tissue healing during post-operative recovery to enable the early detection of major complications, such as anastomotic leaks, and the application of enhanced recovery protocols.<\/p>\n

This new approach to personalized care for patients undergoing gastrointestinal surgery is intended to enhance surgical outcomes and reduce hospital costs.<\/p>\n

\"\"xBar in a clinical setting. Photo credit: Exero Medical<\/em><\/p>\n

This study follows a prior successful clinical study presented in 2023 at the SAGES\u2019 Next Big Thing Technology Session<\/a>.<\/p>\n

Prof. Patricia Sylla MD, FACS, FASCRS, System Chief of Colon and Rectal Surgery for the Mount Sinai Health System, said, \u201cOur goal is to detect complications earlier than we do now and minimize unnecessary stays at the hospital. The xBar system can potentially provide us with a new source of data to support implementation of such enhanced recovery protocols.\u201d Mount Sinai is among several leading medical centers planning to enroll patients in the study.<\/p>\n

Exero Medical CEO Dr. Erez Shor said, \u201cWe have developed the xBar system as a way to translate a wealth of physiological data, which has been hidden to date for the most part, into tangible, actionable clinical data. Our goal is to empower the clinical team to provide precise, personalized care on time, avoid conditions that are likely to become dire and optimize hospital stays.\u201d<\/p>\n

About Exero Medical<\/strong><\/p>\n

Exero Medical was founded in 2018 by MEDX Xelerator<\/a>, an Israeli Innovation Authority incubator, and Clalit Health Services, the largest HMO in Israel. Exero Medical\u2019s goal is to provide high-quality, actionable post-surgery tissue healing monitoring that can save lives, improve prognosis, and reduce costs. The company\u2019s flagship product, xBar, addressing a $7B market, received FDA Breakthrough Designation and is in clinical studies towards a commercial launch in 2025.<\/p>\n

For more information, please visit https:\/\/www.exeromedical.com\/<\/a>
\nFollow Exero Medical on\u00a0LinkedIn<\/a><\/p>\n

Press Contact
\nMarjie Hadad
\nGeneral Manager
\nMust Have Communications
\nOn behalf of Exero Medical
\n917-790-1178
\nmarjie@mhc-pr.com<\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Enrollment to commence in Q1 2024 Or Yehuda, Israel, January 17, 2024 — Exero Medical\u2019s prospective, blinded, multi-center study of xBar has been approved by the WCG. The study, expected to commence during Q1 2024 at several leading US and Israeli hospitals, will enroll about 190 patients undergoing colorectal resection.\u00a0 It will evaluate the performance […]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"acf":[],"yoast_head":"\nExero Medical\u2019s Pivotal Clinical Study of xBar Approved by WCG in the US - MEDX Xelerator<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exero Medical\u2019s Pivotal Clinical Study of xBar Approved by WCG in the US - MEDX Xelerator\" \/>\n<meta property=\"og:description\" content=\"Enrollment to commence in Q1 2024 Or Yehuda, Israel, January 17, 2024 — Exero Medical\u2019s prospective, blinded, multi-center study of xBar has been approved by the WCG. The study, expected to commence during Q1 2024 at several leading US and Israeli hospitals, will enroll about 190 patients undergoing colorectal resection.\u00a0 It will evaluate the performance […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/\" \/>\n<meta property=\"og:site_name\" content=\"MEDX Xelerator\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-17T09:04:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/medxelerator.com\/wp-content\/uploads\/2024\/01\/EXERO.jpg\" \/>\n<meta name=\"author\" content=\"Soli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Soli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/\"},\"author\":{\"name\":\"Soli\",\"@id\":\"https:\/\/medxelerator.com\/#\/schema\/person\/6aa968b04aab58d62b5cdf4743a360de\"},\"headline\":\"Exero Medical\u2019s Pivotal Clinical Study of xBar Approved by WCG in the US\",\"datePublished\":\"2024-01-17T09:04:58+00:00\",\"dateModified\":\"2024-01-17T09:04:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/\"},\"wordCount\":394,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/medxelerator.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medxelerator.com\/wp-content\/uploads\/2024\/01\/EXERO.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/\",\"url\":\"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/\",\"name\":\"Exero Medical\u2019s Pivotal Clinical Study of xBar Approved by WCG in the US - MEDX Xelerator\",\"isPartOf\":{\"@id\":\"https:\/\/medxelerator.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medxelerator.com\/wp-content\/uploads\/2024\/01\/EXERO.jpg\",\"datePublished\":\"2024-01-17T09:04:58+00:00\",\"dateModified\":\"2024-01-17T09:04:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/#primaryimage\",\"url\":\"https:\/\/medxelerator.com\/wp-content\/uploads\/2024\/01\/EXERO.jpg\",\"contentUrl\":\"https:\/\/medxelerator.com\/wp-content\/uploads\/2024\/01\/EXERO.jpg\",\"width\":339,\"height\":254},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/medxelerator.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exero Medical\u2019s Pivotal Clinical Study of xBar Approved by WCG in the US\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/medxelerator.com\/#website\",\"url\":\"https:\/\/medxelerator.com\/\",\"name\":\"MEDX Xelerator\",\"description\":\"Accelerating Science for Life\",\"publisher\":{\"@id\":\"https:\/\/medxelerator.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/medxelerator.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/medxelerator.com\/#organization\",\"name\":\"MEDX XELERATOR\",\"url\":\"https:\/\/medxelerator.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medxelerator.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/medxelerator.com\/wp-content\/uploads\/2024\/01\/MEDX-LOGO.png\",\"contentUrl\":\"https:\/\/medxelerator.com\/wp-content\/uploads\/2024\/01\/MEDX-LOGO.png\",\"width\":819,\"height\":333,\"caption\":\"MEDX XELERATOR\"},\"image\":{\"@id\":\"https:\/\/medxelerator.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/medxelerator.com\/#\/schema\/person\/6aa968b04aab58d62b5cdf4743a360de\",\"name\":\"Soli\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medxelerator.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9f43cd27ac4be2a789af3eadaa07c484?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9f43cd27ac4be2a789af3eadaa07c484?s=96&d=mm&r=g\",\"caption\":\"Soli\"},\"url\":\"https:\/\/medxelerator.com\/author\/soli-dmedxelerator-com\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exero Medical\u2019s Pivotal Clinical Study of xBar Approved by WCG in the US - MEDX Xelerator","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/","og_locale":"en_US","og_type":"article","og_title":"Exero Medical\u2019s Pivotal Clinical Study of xBar Approved by WCG in the US - MEDX Xelerator","og_description":"Enrollment to commence in Q1 2024 Or Yehuda, Israel, January 17, 2024 — Exero Medical\u2019s prospective, blinded, multi-center study of xBar has been approved by the WCG. The study, expected to commence during Q1 2024 at several leading US and Israeli hospitals, will enroll about 190 patients undergoing colorectal resection.\u00a0 It will evaluate the performance […]","og_url":"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/","og_site_name":"MEDX Xelerator","article_published_time":"2024-01-17T09:04:58+00:00","og_image":[{"url":"https:\/\/medxelerator.com\/wp-content\/uploads\/2024\/01\/EXERO.jpg"}],"author":"Soli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Soli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/#article","isPartOf":{"@id":"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/"},"author":{"name":"Soli","@id":"https:\/\/medxelerator.com\/#\/schema\/person\/6aa968b04aab58d62b5cdf4743a360de"},"headline":"Exero Medical\u2019s Pivotal Clinical Study of xBar Approved by WCG in the US","datePublished":"2024-01-17T09:04:58+00:00","dateModified":"2024-01-17T09:04:58+00:00","mainEntityOfPage":{"@id":"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/"},"wordCount":394,"commentCount":0,"publisher":{"@id":"https:\/\/medxelerator.com\/#organization"},"image":{"@id":"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/#primaryimage"},"thumbnailUrl":"https:\/\/medxelerator.com\/wp-content\/uploads\/2024\/01\/EXERO.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/","url":"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/","name":"Exero Medical\u2019s Pivotal Clinical Study of xBar Approved by WCG in the US - MEDX Xelerator","isPartOf":{"@id":"https:\/\/medxelerator.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/#primaryimage"},"image":{"@id":"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/#primaryimage"},"thumbnailUrl":"https:\/\/medxelerator.com\/wp-content\/uploads\/2024\/01\/EXERO.jpg","datePublished":"2024-01-17T09:04:58+00:00","dateModified":"2024-01-17T09:04:58+00:00","breadcrumb":{"@id":"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/#primaryimage","url":"https:\/\/medxelerator.com\/wp-content\/uploads\/2024\/01\/EXERO.jpg","contentUrl":"https:\/\/medxelerator.com\/wp-content\/uploads\/2024\/01\/EXERO.jpg","width":339,"height":254},{"@type":"BreadcrumbList","@id":"https:\/\/medxelerator.com\/exero-medicals-pivotal-clinical-study-of-xbar-approved-by-wcg-in-the-us\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/medxelerator.com\/"},{"@type":"ListItem","position":2,"name":"Exero Medical\u2019s Pivotal Clinical Study of xBar Approved by WCG in the US"}]},{"@type":"WebSite","@id":"https:\/\/medxelerator.com\/#website","url":"https:\/\/medxelerator.com\/","name":"MEDX Xelerator","description":"Accelerating Science for Life","publisher":{"@id":"https:\/\/medxelerator.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/medxelerator.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/medxelerator.com\/#organization","name":"MEDX XELERATOR","url":"https:\/\/medxelerator.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medxelerator.com\/#\/schema\/logo\/image\/","url":"https:\/\/medxelerator.com\/wp-content\/uploads\/2024\/01\/MEDX-LOGO.png","contentUrl":"https:\/\/medxelerator.com\/wp-content\/uploads\/2024\/01\/MEDX-LOGO.png","width":819,"height":333,"caption":"MEDX XELERATOR"},"image":{"@id":"https:\/\/medxelerator.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/medxelerator.com\/#\/schema\/person\/6aa968b04aab58d62b5cdf4743a360de","name":"Soli","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medxelerator.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9f43cd27ac4be2a789af3eadaa07c484?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f43cd27ac4be2a789af3eadaa07c484?s=96&d=mm&r=g","caption":"Soli"},"url":"https:\/\/medxelerator.com\/author\/soli-dmedxelerator-com\/"}]}},"_links":{"self":[{"href":"https:\/\/medxelerator.com\/wp-json\/wp\/v2\/posts\/2776"}],"collection":[{"href":"https:\/\/medxelerator.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medxelerator.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medxelerator.com\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/medxelerator.com\/wp-json\/wp\/v2\/comments?post=2776"}],"version-history":[{"count":6,"href":"https:\/\/medxelerator.com\/wp-json\/wp\/v2\/posts\/2776\/revisions"}],"predecessor-version":[{"id":2783,"href":"https:\/\/medxelerator.com\/wp-json\/wp\/v2\/posts\/2776\/revisions\/2783"}],"wp:attachment":[{"href":"https:\/\/medxelerator.com\/wp-json\/wp\/v2\/media?parent=2776"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medxelerator.com\/wp-json\/wp\/v2\/categories?post=2776"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medxelerator.com\/wp-json\/wp\/v2\/tags?post=2776"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}